Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.67 |
| ▸ | HTR1A | P08908 | 7/20 | 0.55 |
| ▸ | HTR3A | P46098 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | HTR6 | P50406 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2469257 | 0.89 | HTR2C (0.67) | HTR2CHTR1AHTR3ACYP1A2CYP3A4 | |
| SCHEMBL3543522 | 0.85 | HTR2C (0.55) | HTR2CHTR1AHTR3ACYP1A2CYP3A4 | |
| SCHEMBL3549082 | 0.84 | HTR2C (0.54) | HTR2CHTR1AHTR3ACYP1A2CYP3A4 | |
| SCHEMBL3419684 | 0.81 | HTR2C (0.52) | HTR2CHTR1AHTR3ACYP1A2CYP3A4 | |
| SCHEMBL5584737 | 0.81 | HTR2C (1.00) | HTR2CHTR1AHTR6SLC6A2SLC6A4 | |
| SCHEMBL3421798 | 0.80 | HTR2C (0.51) | HTR2CHTR1AHTR3ACYP1A2CYP3A4 | |
| SCHEMBL19404494 | 0.80 | HTR1A (0.56) | HTR2CHTR1AHTR3ACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL21855666 | 0.79 | HTR2C (1.00) | HTR2CHTR1AHTR6SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL31109384 | 0.79 | HTR2C (1.00) | HTR2CHTR1AHTR6SLC6A2SLC6A4 | |
| SCHEMBL3544453 | 0.79 | HTR2C (0.50) | HTR2CHTR1AHTR3ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100242-A1 | such as 4-[2-(4-Chloro-phenylsulfanyl)-5-trifluoromethyl-phenyl]-piperidine, used as antidepressants and anxiolytic agents; treatment of panic and obsessive compulsive disorders | H.LUNDBECK A/S (DK) | 2006-05-11 | — | — | US | claimed |
| EP-2564837-B1 | ENTERIC TABLET | TAKEDA PHARMACEUTICALS CO (JP) | 2019-01-30 | — | — | EP | disclosed |
| US-8920840-B2 | Enteric tablet | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-30 | — | — | US | disclosed |
| CN-103096879-B | Enteric coated tablet | TAKEDA PHARMACEUTICAL | 2014-12-10 | — | — | CN | disclosed |
| US-20130115291-A1 | ENTERIC TABLET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-09 | — | — | US | disclosed |
| CN-103096879-A | Enteric coated tablet | TAKEDA PHARMACEUTICAL | 2013-05-08 | — | — | CN | disclosed |
| EP-2564837-A1 | ENTERIC TABLET | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-7732463-B2 | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2010-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100242-A1 | such as 4-[2-(4-Chloro-phenylsulfanyl)-5-trifluoromethyl-phenyl]-piperidine, used as antidepressants and anxiolytic agents; treatment of panic and obsessive compulsive disorders | HTR4, HTR5A, TPH1 | HTR2C 4/4885HTR1A 11/4885HTR3A 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.